Mark A. Hardy
Encyclopedia
Mark A. Hardy is Auchincloss Professor of Surgery, Director Emeritus of the Transplant Centre, and Vice Chairman and Residency Program Director of the Department of Surgery at the Columbia University College of Physicians and Surgeons
and NewYork-Presbyterian Hospital
in New York City.
Hardy is most recognized for co-founding the New York Organ Donor Network in 1978 (NYODN 2006). In addition to his work in transplantation, in the earlier part of his career he made several contributions to the development of prosthetic vascular grafts and the development and studies of biologic function of thymic hormones, both experimentally and clinically.
Hardy laid another cornerstone of organ transplant
medicine by helping found the program for dialysis and kidney transplantation at NewYork-Presbyterian Hospital
. He based the new program on the principle of combined clinical care between surgeons and nephrologists during a time when renal transplant programs were managed by one or the other discipline, never by both at once (CUMC Programs 2007). This cooperation between disciplines led to major contributions in immunogenetics
, immunosuppression
, and treatment of autoimmune diseases and lymphoma
(CUMC Programs 2007).
His most recent focus has been on cellular transplantation with emphasis on islet transplantation. Hardy is Principal Investigator of a multicenter clinical trial exploring a combination of two immunosuppressant drugs, sirolimus and tacrolimus (CUMC 2007 Kidney). He also currently a member of several multiinstitutional studies of immunosuppressive agents which are individually sponsored by Novartis
, Astellas and Bristol Myers.
, Sangstat, Hoffmann-La Roche
, Novartis
, Astellas, and Gore.
Columbia University College of Physicians and Surgeons
Columbia University College of Physicians and Surgeons, often known as P&S, is a graduate school of Columbia University that is located on the health sciences campus in the Washington Heights neighborhood of Manhattan...
and NewYork-Presbyterian Hospital
NewYork-Presbyterian Hospital
NewYork–Presbyterian Hospital is a prominent university hospital in New York City affiliated with two Ivy League medical schools: Columbia University's College of Physicians and Surgeons and Cornell University's Weill Medical College. It is composed of two distinct medical centers, Columbia...
in New York City.
Hardy is most recognized for co-founding the New York Organ Donor Network in 1978 (NYODN 2006). In addition to his work in transplantation, in the earlier part of his career he made several contributions to the development of prosthetic vascular grafts and the development and studies of biologic function of thymic hormones, both experimentally and clinically.
Hardy laid another cornerstone of organ transplant
Organ transplant
Organ transplantation is the moving of an organ from one body to another or from a donor site on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative medicine is allowing scientists and engineers to create organs to be...
medicine by helping found the program for dialysis and kidney transplantation at NewYork-Presbyterian Hospital
NewYork-Presbyterian Hospital
NewYork–Presbyterian Hospital is a prominent university hospital in New York City affiliated with two Ivy League medical schools: Columbia University's College of Physicians and Surgeons and Cornell University's Weill Medical College. It is composed of two distinct medical centers, Columbia...
. He based the new program on the principle of combined clinical care between surgeons and nephrologists during a time when renal transplant programs were managed by one or the other discipline, never by both at once (CUMC Programs 2007). This cooperation between disciplines led to major contributions in immunogenetics
Immunogenetics
Immunogenetics is the branch of medical research that explores the relationship between the immune system and genetics.Autoimmune diseases, such as type 1 diabetes, are complex genetic traits which result from defects in the immune system. Identification of genes defining the immune defects may...
, immunosuppression
Immunosuppression
Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other...
, and treatment of autoimmune diseases and lymphoma
Lymphoma
Lymphoma is a cancer in the lymphatic cells of the immune system. Typically, lymphomas present as a solid tumor of lymphoid cells. Treatment might involve chemotherapy and in some cases radiotherapy and/or bone marrow transplantation, and can be curable depending on the histology, type, and stage...
(CUMC Programs 2007).
His most recent focus has been on cellular transplantation with emphasis on islet transplantation. Hardy is Principal Investigator of a multicenter clinical trial exploring a combination of two immunosuppressant drugs, sirolimus and tacrolimus (CUMC 2007 Kidney). He also currently a member of several multiinstitutional studies of immunosuppressive agents which are individually sponsored by Novartis
Novartis
Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry...
, Astellas and Bristol Myers.
Honors
Hardy has been a professor in about 30 institutions and delivered over 10 eponymous lectures worldwide. He has received honoraria for lectures in the past from UpjohnUpjohn
The Upjohn Company was a pharmaceutical manufacturing firm founded in 1886 in Kalamazoo, Michigan by Dr. William E. Upjohn, an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested...
, Sangstat, Hoffmann-La Roche
Hoffmann-La Roche
F. Hoffmann-La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange....
, Novartis
Novartis
Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry...
, Astellas, and Gore.
- Honorary Doctor of Philosophy, Hallym UniversityHallym UniversityHallym University is a private university which is located in Chuncheon, Gangwon, Republic of Korea. Hallym University was established in 1982. In 1995 it was designated by the Ministry of Education as one of a handful of universities entitled to receive the financial support of the Ministry for...
, South Korea, 2004 - Honoris Causa Doctoris, University of WarsawUniversity of WarsawThe University of Warsaw is the largest university in Poland and one of the most prestigious, ranked as best Polish university in 2010 and 2011...
, 2000 - Honorary Fellowship in the Polish Surgical Society, 1999
- NIH Academic Scholar in Surgery, 1968–1971
Selected publications
Hardy is an editor of Transplantation and has published more than 300 articles on subjects varying from surgical techniques to basic immunology. He was also editor of one of the first books on xenotransplantation, Xenograft 25.- Loss, Grief & Care. M.A. Hardy, J. Kiernan, A.H. Kutscher, L. Cahill and A. Benvenisty (eds.). The Haworth Press, Inc., New York. 1991.
- Xenograft 25. M.A. Hardy (ed.). Elsevier Science Publishers B.V., Amsteram. 1989.
- Transplantation of the Endocrine Pancreas in Diabetes Mellitus. R. van Schilfgaarde, M.A. Hardy (eds.). Elsevier Science Publishers B.V., Amsterdam. 1988.
- Evaluation of a°. A 360 Night-float System for General Surgery: A Response to Mandated Work-hours Reduction. MJ Goldstein, E Kim, WD Widmann, MA Hardy. Current Surgery. 61(5):445-451. 2004.
- The Use of Allopeptides in Tolerance Induction In Rodents. MA Hardy, OO Oluwole, HA Depaz, R Gopinathan, AO Ali, M Garrovillo and SF Oluwole. Graft. 2003.